Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | LDHA | P00338 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16496718 | 0.92 | MAPT (0.49) | MAPK14SMN1; SMN2KMT2AHPGDMAPT | |
| SCHEMBL16496426 | 0.91 | HPGDS (0.52) | MAPK14SMN1; SMN2KMT2AHPGDMAPT | |
| SCHEMBL16495974 | 0.83 | HPGDS (0.53) | MAPK14SMN1; SMN2KMT2AHPGDMAPT | |
| SCHEMBL16495439 | 0.79 | HPGDS (0.56) | MAPTRAB9ANPC1LMNAALDH1A1 | |
| SCHEMBL5426580 | 0.79 | KDM4E (0.67) | SMN1; SMN2KMT2AHPGDMAPTGAA | |
| SCHEMBL16495487 | 0.79 | HPGDS (0.58) | MAPK14SMN1; SMN2KMT2AMAPTRAB9A | |
| SCHEMBL13450252 | 0.78 | SMN1; SMN2 (0.52) | SMN1; SMN2KMT2AHPGDMAPTGAA | |
| SCHEMBL16496188 | 0.78 | NPC1 (0.56) | MAPK14SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL16496067 | 0.78 | HPGDS (0.57) | MAPK14SMN1; SMN2MAPTRAB9ANPC1 | |
| SCHEMBL16495723 | 0.78 | MAPT (0.45) | SMN1; SMN2KMT2AMAPTGAANAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110306597-A1 | Nicotinamide Derivatives | CRAWFORTH JAMES MICHAEL (GB) | 2011-12-15 | — | — | US | disclosed |
| US-20110306597-A1 | Nicotinamide Derivatives | CRAWFORTH JAMES MICHAEL (GB) | 2011-12-15 | — | — | US | disclosed |
| EP-2307378-A1 | NICOTINAMIDE DERIVATIVES | Pfizer Limited (GB) | 2011-04-13 | — | — | EP | disclosed |
| WO-2009153721-A1 | NICOTINAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009153721-A1 | NICOTINAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306597-A1 | Nicotinamide Derivatives | NNT, NAMPT, NQO1 | MAPK14 2795/4885SMN1; SMN2 1659/4885KMT2A 3206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.